GlassScriptPhysician profile
Yakov Ryabov
NPI 1912909615
$9,843.06
in general payments reported to CMS, 2019-2025
48 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $990 · 2021: $1,675 · 2022: $1,654 · 2023: $1,076 · 2024: $1,522 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,251.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,217.08 | 2020-2025 | Vraylar, Linzess, Creon |
| Novo Nordisk INC | $799.08 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $600.26 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $571.35 | 2019-2022 | |
| Lilly USA, LLC | $461.29 | 2019-2025 | Jardiance, Mounjaro |
| Corcept Therapeutics | $460.57 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.01 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $359.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $313.09 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $295.45 | 2021-2025 | Caplyta |
| Pfizer INC. | $287.57 | 2019-2025 | |
| Amarin Pharma, INC. | $285.20 | 2019-2021 | |
| Mylan Specialty L.P. | $245.01 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $217.26 | 2022-2024 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yakov Ryabov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.